Pulmonary Disease

Respiratory·MeSH: Lung Diseases

Prevalence

6000.0 / 100K

Incidence

200.0 / 100K/yr

60 drugs in development·23 companies·6 clinical trials

Drug Pipeline by Phase

Approved(10)

Drug	Company
ANORO ELLIPTA	Innoviva, Inc. (INVA)
breyna	Mylan II B.V. (MYL)
Ohtuvayre	Verona Pharma plc (VRNA)
RELVAR/BREO ELLIPTA	Innoviva, Inc. (INVA)
Trelegy	Royalty Pharma plc (RPRX)
Tyvaso (nebulized)	UNITED THERAPEUTICS Corp (UTHR)
Tyvaso DPI	UNITED THERAPEUTICS Corp (UTHR)
wixela inhub	Mylan II B.V. (MYL)
yupelri	Theravance Biopharma, Inc. (TBPH)
yupelri	Mylan II B.V. (MYL)

Phase 3(19)

Drug	Company
AZD6793	ASTRAZENECA PLC (AZN)
bgf	ASTRAZENECA PLC (AZN)
bgf mdi 320/14.4/9.6 μg	ASTRAZENECA PLC (AZN)
Ensifentrine (nebulized) - asthma	Verona Pharma plc (VRNA)
Ensifentrine (nebulized) - bronchiectasis	Verona Pharma plc (VRNA)
Ensifentrine (nebulized) - cystic fibrosis	Verona Pharma plc (VRNA)
Ensifentrine / glycopyrrolate fixed-dose combination	Verona Pharma plc (VRNA)
Ensifentrine 1.5 mg	Verona Pharma plc (VRNA)
Ensifentrine 3 mg	Verona Pharma plc (VRNA)
gff mdi 14.4/9.6 μg	ASTRAZENECA PLC (AZN)
itepekimab	Sanofi (SNY)
Itepekimab	Sanofi (SNY)
itepekimab sar440340	Sanofi (SNY)
Omalizumab	Cidara Therapeutics, Inc. (CDTX)
prochymal	Mesoblast Limited (MESO)
Tezepelumab	ASTRAZENECA PLC (AZN)
Tozorakimab	ASTRAZENECA PLC (AZN)
tozorakimab dose regimen 1	ASTRAZENECA PLC (AZN)
tozorakimab dose regimen 2	ASTRAZENECA PLC (AZN)

Phase 2(15)

Drug	Company
dupilumab	Sanofi (SNY)
Dupilumab	Sanofi (SNY)
glyceryl bromide/formoterol inhalation aerosol	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
Glycopyrrolate	Verona Pharma plc (VRNA)
Glycopyrrolate 21.25 mcg	Verona Pharma plc (VRNA)
Glycopyrrolate 42.5 mcg	Verona Pharma plc (VRNA)
inopulse	Bellerophon Therapeutics, Inc. (BLPH)
lunsekimig	Sanofi (SNY)
prochymal	Mesoblast Limited (MESO)
spr720	Spero Therapeutics, Inc. (SPRO)
tqc3721	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
tqc3927 inhalation aerosol	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
verekitug	Upstream Bio, Inc. (UPB)
Verekitug	Crinetics Pharmaceuticals, Inc. (CRNX)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

Phase 1(2)

Drug	Company
APG333	Apogee Therapeutics, Inc. (APGE)
pur1800	Pulmatrix, Inc. (PULM)

Preclinical(5)

Drug	Company
companion diagnostic tests for asthma	bioAffinity Technologies Inc. (BIAF)
ent-576	ENTEST GROUP, INC. (ETNI)
f528	GYRE THERAPEUTICS, INC. (GYRE)
labp-73	Landos Biopharma, Inc. (LABP)
zw1528	Zymeworks Inc. (ZYME)

Phase 2/Phase 3(2)

Drug	Company
pf-07275315-dose 2	PFIZER INC (PFE)
pf-07275315-dose 3	PFIZER INC (PFE)

Phase 4(7)

Drug	Company
BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL	ASTRAZENECA PLC (AZN)
budesonide/glycopyrrolate/formoterol	ASTRAZENECA PLC (AZN)
budesonide/glycopyrronium/formoterol	ASTRAZENECA PLC (AZN)
Nebulized Tyvaso	UNITED THERAPEUTICS Corp (UTHR)
treatment a	ASTRAZENECA PLC (AZN)
treatment b	ASTRAZENECA PLC (AZN)
treatment c	ASTRAZENECA PLC (AZN)

BioSniper tracks 60 drugs in development for Pulmonary Disease across 23 companies.

There are 6 clinical trials targeting Pulmonary Disease tracked by BioSniper.

The estimated prevalence of Pulmonary Disease is approximately 6000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.